NGS Expert Blog

Since the NGS Expert Blog grew up, it is good to stop for a moment and reflect on the last 20 months since it went live. The NGS expert team at Eurofins MWG Operon spent a lot of time writing posts that interest you. From time to time it is important to streamline our work with your interests and needs. So, please share your feedback with us.

What posts interest you? Do you like the mobile version? What do you think about the frequency of the posts? Etc.

Just submit your vote (s. poll on the right hand side) or send me an email at carolagrimminger@eurofins.com. I am looking forward to your thoughts!

The markets for DNA sequencing and analysis products are charaterised by rapidly advancing technology and a distinct trend toward consolidation of suppliers. The worldwide market for next generation sequencing platforms is currently estimated by $1.5 Billion (~€1.2 Milliard). The U.S. and Europe exhibit the highest market penetration for next generation sequencing. Oher parts of the world are projected to see higher compound annual growth rates of up to 13%. As next generation DNA sequencing platforms become increasingly affordable, the cost of sequencing a human genome will soon fall below the $1,000 (~€800) price point.

TriMark predicts that as the costs of acquiring and operating sequencing machines continue to drop, the markets for DNA sequencing will continue to grow in size and scope. Read more in its newly published “DNA Sequencing and PCR Markets” report. Find the free executive summary in the sample copy.

In 2011, University of Münster researchers reported their sequencing of an Escherichia coli strain behind an outbreak in Germany, showing that real-time sequencing was feasible. Then they characterized a K. pneumoniae strain that infected patients in a Dutch hospital. This information was used to develop a multiplex PCR-based assay for the disease.

For the K. pneumoniae outbreak at the US National Institutes of Health’s Clinical Center, Julie Segre and her colleagues sequenced isolates from the 18 infected patients using a 454/Roche machine. From their Newbler assembly and subsequent analysis, they found that isolates from patient 1 and patient 2 differed by two SNPs out of the 6 megabase K. pneumoniae genome, indicating they were infected with the same strain. …

As the cost of sequencing is dropping, major medical centers could soon implement whole genome sequencing to monitor disease exposure of patients. “If the analysis is that you are spending $100,000 to have an organ transplant or go through some very intensive cancer treatment that involves a few nights’ stay in the ICU,” Segre says, “at that point, putting up $500 to sequence an organism that may be affecting another patient in the ICU. … I could imagine in the future that that becomes part of the economic model.”

Read the whole GenomeWeb article at http://bit.ly/Qu3tRX

We are happy to extend our next generation sequencing capabilities with the new Illumina HiSeq 2500 and Illumina MiSeq. Thanks to these new machines, we can provide customers with unsurpassable NGS services at high accuracy rates and shorter turnaround time (TAT). Read more at http://bit.ly/OTv9AP

We asked, for which kind of application do you use the Roche GS FLX+, the GS FLX Titanium or GS Junior sequencing technology providing read length of up to 700 bp? 36 people answered the poll:

Please find on the right hand side our new poll and add your voice!

Illumina product experts discuss within 4 videos

1. what it takes to get a good genome out of a sequencing system,
2. what attributes of a sequencing system contribute to the quality of a sequencing data set,
3. the hidden costs of accuracy and
4. how next generation sequencing is moving into the clinic because of a better understanding of accuracy.

Please be tolerant, they’re from Marketing

Eric Green is talking about the genomic landscape. Please enjoy the great presentation – starting at min 6.00.

The Genomatix Genome Analyzer has been chosen by a panel of 30 experts to be awarded.

Genomatix has been awarded the “INDUSTRIEPREIS 2012″ in the biotechnology category at the Hannover Messe (Germany), the world’s biggest technology trade show. They have received it for its data analysis and interpretation platform Genomatix Genome Analyzer (GGA).

“…It’s a big motivation for the whole team to come up with even more innovative ideas on how to deal with the increasing deluge of Next Generation Sequencing data”, adds Dr. Martin Seifert, CEO of Genomatix, “getting an award that explicitly rewards products of technological and social value underlines that NGS is quickly moving from a research tool into the broader field of clinical application.”

The upcoming conference in August will showcase expanding applications of NGS shaping the industry.

Agenda topics include:

• RNA-seq
• What’s next in sequencing platforms?
• Nanopore sequencing
• Desktop sequencers
• Structural variation

Attend Cambridge Healthtech Institute’s Applying Next Generation Sequencing to learn from large sequencing centers, core laboratories, and specialized groups as they share their practical knowledge, real-world experiences and solutions.

The conference takes place August 13-15 in Providence, Rhode Island, USA. Visit there our worldwide exclusive cooperation partner Genomatix.

Note: If you register by Friday, July 13 and save up to $200.  Registration includes access to CHI’s Fifth Annual Next-Generation Sequencing Data Analysis conference running concurrently.

Eurofins MWG Operon and Integrated Genomics have announced a cooperation agreement to combine their expertise in sequencing and analysis services for microbial, fungal and algal organisms. The goal of the cooperation is to provide customers “one-stop-shopping” for complete genome projects that delivers analysis results from the raw extracted DNA. Read the press release.